Comprehensive cardiac rehabilitation (CR) is an

Size: px
Start display at page:

Download "Comprehensive cardiac rehabilitation (CR) is an"

Transcription

1 Circulation Journal doi: /circj.CJ ORIGINAL ARTICLE Cardiac Rehabilitation Impact of Physical Activity on Coronary Plaque Volume and Components in Acute Coronary Syndrome Patients After Early Phase II Cardiac Rehabilitation Miho Nishitani-Yokoyama, MD; Katsumi Miyauchi, MD; Kazunori Shimada, MD; Takayuki Yokoyama, MD, PhD; Shohei Ouchi, MD, PhD; Tatsuro Aikawa, MD, PhD; Mitsuhiro Kunimoto, MD; Miki Yamada, PhD; Akio Honzawa, BSc; Shinya Okazaki, MD; Hiroyuki Daida, MD Background: Cardiac rehabilitation (CR) is an established multidisciplinary secondary preventive program. We investigated the effects of CR involving intensive physical activity (PA) on coronary plaque volume and components in patients with acute coronary syndrome (ACS). Methods and Results: We enrolled 32 consecutive patients with ACS in early phase II CR and randomly assigned them to an intensive CR group (n=18; CR participation twice/week, daily PA 9,000 steps) or a standard CR group (n=14; CR participation once/2weeks, daily PA 6,000 steps). Serial integrated backscatter intravascular ultrasound was performed for non-culprit lesions at baseline and after 8 months. Baseline clinical data were identical between the 2 groups. Unexpectedly, CR participation and PA did not differ significantly between the 2 groups, and there was no significant difference in plaque volume (PV) or components between the 2 groups. Subsequently, we classified the patients into 2 groups according to median PA (7,000 steps). There were significant differences in percent change of PV and of lipid volume between these 2 groups. In addition, these changes were negatively and independently correlated with PA. Conclusions: No significant difference was observed in PV or components between the intensive CR and the standard CR groups. Intensive PA, however, may retard coronary PV and ameliorate lipid component in patients with ACS participating in late phase II CR. Key Words: Acute coronary syndrome; Cardiac rehabilitation; Coronary plaque stabilization; Integrated backscatter intravascular ultrasound; Physical activity Comprehensive cardiac rehabilitation (CR) is an established multidisciplinary secondary prevention program in patients with acute coronary syndrome (ACS), those receiving coronary artery bypass grafting (CABG), and those with heart failure. 1 CR is effective in modulating risk factors and reducing the incidence of future cardiovascular events. 2 According to the guidelines of the Japanese Circulation Society and the American Association of Cardiovascular and Pulmonary Rehabilitation, it is recommended to perform aerobic exercises, such as walking, running, and cycling, for 30 min each time, 3 4 times per week, based on exercise tolerance test. 3 Comprehensive CR and/or multifactorial intervention has been shown to inhibit angiographic minimal lumen stenosis. 4,5 We recently showed that coronary plaque changes in patients with ACS were significantly and negatively correlated with physical activity (PA). 6 Therefore, CR with intensive PA may have beneficial effects on coronary plaque regression in patients with ACS. Recently, advances in coronary plaque imaging, such as serial integrated backscatter intravascular ultrasound (IB- IVUS), have enabled physicians to observe the morphology of the plaque and accurately measure plaque volume (PV). Indeed, recent studies on statins using IB-IVUS have demonstrated significant plaque regression and stabilization. 7,8 Currently, however, there are no studies on the effect of CR involving intensive PA on PV and components using IB-IVUS. The aim of this study was therefore to investigate the effects of CR involving intensive PA on coronary PV and components in patients with ACS. Received June 26, 2018; revised manuscript received September 12, 2018; accepted September 26, 2018; J-STAGE Advance Publication released online November 8, 2018 Time for primary review: 26 days Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo (M.N.-Y., K.M., K.S., T.Y., S. Ouchi, T.A., M.K., S. Okazaki, H.D.); Cardiovascular Rehabilitation and Fitness, Juntendo University Hospital, Tokyo (M.N.-Y., K.S., M.Y., A.H.), Japan Mailing address: Hiroyuki Daida, MD, Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo , Japan. daida@juntendo.ac.jp ISSN All rights are reserved to the Japanese Circulation Society. For permissions, please cj@j-circ.or.jp

2 2 NISHITANI-YOKOYAMA M et al. Figure 1. Subject selection. ACS, acute coronary syndrome; CAG, coronary angiography; CR, cardiac rehabilitation; IVUS, intravascular ultrasound; PCI, percutaneous coronary intervention. Methods Study Protocol and Subjects This study was a prospective, randomized, open-label, single-center trial to assess the effects of CR involving intensive PA on coronary PV and components in patients with ACS using serial volumetric IVUS and IB-IVUS analysis. All patients underwent emergency coronary stenting. At baseline and 8 months after percutaneous coronary intervention (PCI), serial volumetric IVUS and IB-IVUS were performed to assess changes in coronary plaque and components in non-culprit lesions (non-pci sites of the culprit vessel). Based on eligibility criteria, 51 consecutive patients with ACS admitted to Juntendo University Hospital between February 2013 and January 2016 were enrolled. ACS was defined as high-risk unstable angina, non-st-elevated myocardial infarction (MI), or ST-elevated MI. MI was diagnosed on a 2-fold increase in serum creatine phosphokinase and positivity for troponin T. 9 Exclusion criteria included failed PCI, diseased bypass graft, recommended CABG, cardiogenic shock, hepatic or renal dysfunction (creatinine 2.0 mg/dl, alanine aminotransferase and aspartate aminotransferase 2-fold the upper limits of normal), inflammatory disease, or known malignant disease. Patients were randomly assigned to an intensive CR group (late phase II CR participation, twice per week and step count, 9,000/day) or a standard CR group (late phase II CR participation, once/2 weeks and step count, 6,000/day) 72 h following PCI. Randomization was stratified according to age, ejection fraction, and presence or absence of diabetes. Following the procedure, all patients participated in early-phase II CR. We recommended all patients to participate in late-phase II CR after discharge and to perform walking in accordance with their exercise protocol. Follow-up visits were scheduled every 4 weeks following PCI. According to randomization, exercise content and daily PA were checked during each visit. Baseline measurements included IVUS and biochemistry data on admission and cardiopulmonary exercise test (CPX) on discharge. Follow-up IVUS data, biochemistry data, and CPX were repeated after 8 months. This study was conducted in accordance with the Declaration of Helsinki and approved by the institutional review board of the ethics committee of Juntendo University Hospital. All subjects provided written informed consent prior to participating in the study. This study was registered with the University Hospital Medical Information Network (UMIN ). IVUS and IB-IVUS All IVUS was performed using the same equipment. Briefly, a 40-MHz, 2.5-Fr IVUS catheter (ViewIT TM, Terumo, Tokyo, Japan) was advanced into the culprit vessel meeting specific inclusion criteria and positioned as distally as patient safety permitted following 0.2 mg i.c. nitroglycerin. Pullback was automatically performed at 0.5 mm/s. All measurements were performed at the end of the study. Grayscale IVUS and IB-IVUS were performed by 2 experienced independent observers blinded to the clinical and angiographic information using VISIATRAS TM (Terumo). We had previously performed several IVUS trials, including ESTABLISH, JAPAN-ACS, and ALPS-J Following the methods of these studies, the target segment was determined at a non-pci site (5 mm proximal or distal to the PCI site) of the culprit vessel with a reproducible index, usually a branch site, on the PCI vessel. Baseline and follow-up IVUS were reviewed side by side on a display, and the target segment was selected. Local landmarks, such as side branches and calcium deposits, as well as the topology of the lumen were used to ensure comparable frames. Grayscale IVUS analysis included vessel volume, lumen volume, and PV. PV was calculated as vessel volume lumen volume. Percent change in PV was defined as the change in PV (follow-up baseline PV)/baseline PV. Lesions meeting any of the following criteria were not investigated: calcification, kinking, chronic complete occlusion, bypass graft site, site of coronary atherectomy prior to PCI, located at the left main trunk, small vessel (<2.0 mm), or location of distal protection device. IB-IVUS analysis was performed as previously reported. 7,8 Briefly, integrated backscatter values for each tissue

3 Physical Activity and Coronary Plaque in ACS 3 Table 1. Baseline Patient Characteristics Intensive CR group (n=18) Standard CR group (n=14) P-value Age (years) 58.0± ± Male 17 (94) 13 (93) 0.85 Hypertension 10 (56) 10 (71) 0.35 Diabetes mellitus 6 (33) 5 (35) 0.88 Dyslipidemia 17 (94) 13 (93) 0.85 Current smoking 12 (66) 5 (36) 0.05 Family history 9 (50) 3 (21) 0.10 Prior CAD 1 (6) 1 (7) 0.85 ACS classification ST-elevated MI 9 (50) 3 (21) Non-ST-elevated MI 6 (33) 11 (79) 0.15 Unstable angina 3 (17) 0 (0) Diseased vessels Single 13 (72) 9 (64) Double 4 (22) 5 (36) 0.50 Triple 1 (6) 0 (0) Culprit vessel RCA 3 (17) 6 (43) LAD 14 (78) 7 (50) 0.23 LCX 1 (5) 1 (7) Maximum CK (IU/L) 2,208±2,590 2,174±1, EF (%) 52.7± ± Medication at admission RAS-I 7 (39) 6 (43) 0.41 β-blockers 7 (39) 4 (29) 0.54 CCB 2 (11) 5 (36) 0.09 Statin 10 (56) 4 (29) 0.12 EPA 1 (6) 1 (7) 0.85 α-gi 0 1 (7) 0.73 DPP-4 inhibitors 0 1 (7) 0.73 Insulin 0 (0) 1 (7) 0.73 Medication at discharge DAPT 18 (100) 14 (100) 0.36 RAS-I 16 (89) 14 (100) 0.24 β-blockers 14 (78) 13 (93) 0.24 CCB 2 (11) 1 (7) 0.71 Statin 18 (100) 14 (100) 0.36 Ezetimibe 3 (17) 2 (14) 0.85 EPA 1 (6) 1 (7) 0.85 α-gi 1 (6) 1 (7) 0.85 DPP-4 inhibitors 2 (11) 1 (7) 0.28 Insulin 0 (0) 3 (21) 0.04 Data given as mean ± SD or n (%). α-gi, α-glucosidase inhibitors; ACS, acute coronary syndrome; CAD, coronary artery disease; CCB, calcium-channel blockers; CK, creatine kinase; CR, cardiac rehabilitation; DAPT, dual antiplatelet therapy; DPP-4, dipeptidyl peptidase 4; EF, ejection fraction; EPA, eicosapentaenoic acid; LAD, left anterior descending artery; LCX, left circumflex artery; MI, myocardial infarction; RAS-I, renin-angiotensin-aldosterone system inhibitors; RCA, right coronary artery. component were calculated as an average power using a fast Fourier transform of the frequency component of the backscattered signal (measured in decibels) from a small volume of tissue. IB values for each plaque component (calcified, fibrous, dense fibrous, and lipid) were determined. The percentages of calcification (calcified area/plaque area), fibrous area (fibrous area/plaque area), dense fibrous area (dense fibrous area/plaque area), and lipid area (lipid area/ plaque area) were automatically calculated using the IB-IVUS system at 0.1-mm intervals. Three-dimensional analysis of grayscale IVUS and IB-IVUS was conducted to obtain the PV of each IB-IVUS component. Subsequently, the percentages of calcified volume, fibrous volume (FV), dense FV, and lipid volume (LV) were also calculated.

4 4 NISHITANI-YOKOYAMA M et al. Table 2. Comparison of Anthropometric Parameters, Exercise Tolerance, Physical Activity and Lipid Profiles Between the Intensive and Standard Groups Intensive CR group (n=18) Standard CR group (n=14) Baseline After Baseline After Anthropometry BMI (kg/m 2 ) 24.8± ± ± ±3.7 WC (cm) 90.6± ±6.6*,# 85.2± ±9.6* HC (cm) 94.4± ± ± ±5.1* Fat weight (kg) 18.4± ± ± ±5.6 Lean body weight (kg) 51.2± ± ± ±6.2 Exercise tolerance Peak V O2 (ml/kg/min) 17.2± ±4.3* 15.8± ±3.5* Late phase II CR 12±10 8±6 Daily PA (steps/day) 6,857±2,046 7,789±2,249 6,249±2,477 7,760±2,616* Lipid profile and glucose metabolism LDL-C (mg/dl) 141±47 79±19* 119±39 67±18* HDL-C (mg/dl) 42±9 42±10 40±10 40±11 LH ratio 3.5± ±0.7* 3.1± ±0.6* TG (mg/dl) 183± ±57 152±65 134±46 FBS (mg/dl) 110±40 97±15 132±50 101±16* HbA1c (%) 5.9± ±0.4 # 6.4± ±0.7 Data given as mean ± SD. *P<0.05 vs. baseline, **vs. standard group at baseline, # vs. standard group after 8 months. BMI, body mass index; CR, cardiac rehabilitation; FBS, fasting blood sugar; HbA1c, hemoglobin A1c; HC, hip circumference; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LH, LDL-C/HDL-C; PA, physical activity; TG, triglyceride; V O2, oxygen consumption; WC, waist circumference. Early Phase II CR The CR program, consisting of warm-up stretching, aerobic exercise, and cool down, was scheduled once daily in the hospital, as described previously. 12,13 Aerobic exercise consisted of a cycle ergometer, treadmill, and walking (in-room track). The total time for aerobic exercise was approximately 20 min. Exercise intensity was individually prescribed at the anaerobic threshold (AT) as measured on ergometer test using expiratory gas analysis or a rating of on the standard Borg s perceived exertion scale. At the beginning of CR, all subjects were instructed to follow the phase II diet recommended by the American Heart Association. Moreover, at baseline, an educational program was provided by physicians, nurses, and dietitians to each subject regarding coronary artery disease (CAD) and its risk factors. Measurements Body composition and exercise tolerance were assessed at the beginning and at 8-month follow-up. Anthropometric parameters were assessed using body mass index and waist size. The percentages of body fat and lean body weight were measured using the Tanita MC-780A Body Composition Analyzer (Tanita, Tokyo, Japan), based on bioelectrical impedance analysis. The derivation of body volume, coupled with the measurement of body mass, permits the calculation of body density and the subsequent estimation of percent fat and fat-free mass. Patients underwent ergometer testing (Strength Ergo8, Nihon Kohden, Tokyo, Japan) using an expiratory gas analysis machine (AE-310s, Minato Medical Science, Osaka, Japan) to measure peak oxygen consumption (peak V O2) and oxygen uptake at AT. Following a period of resting, warm-up was performed for a few minutes at 0 W, followed by ramp loading (10 W/min) until subjective exhaustion, progressive angina, ST-segment depression ( 2 mm), or sustained tachyarrhythmia. The point of AT was determined using the V-slope method. Daily PA was evaluated using a pedometer (Lifecoder, Suzuken, Nagoya, Japan) recording mean step count and calculating the mean energy of PA for up to 60 days. Statistical Analysis Results are expressed as mean ± SD and were analyzed using JMP version 12 for Windows (SAS Institute, Cary, NC, USA.). Comparisons between the active and inactive groups were performed using Student s t-test. Correlation coefficients were determined using linear regression analysis. Stepwise multiple regression analysis was used to determine independent predictors of change in plaque and lipid PV. Statistical significance of correlation coefficients was determined using the method of Fisher and Yates. P<0.05 denoted statistical significance. Results Subjects A total of 51 patients were enrolled between February 2013 and January 2016 and randomly assigned to an intensive CR (n=25) or a standard CR (n=26) group. Of the 51 patients, 19 (intensive group; n=7, standard group; n=12) were excluded because of poor IVUS quality. Finally, 32 patients (intensive group; n=18, standard group; n=14) were clinically assessed, including IVUS measurements at baseline and follow-up, and were included in the intentionto-treat analysis reported here (Figure 1). Clinical Characteristics Subject clinical characteristics are listed in Table 1. No significant differences in age, sex, coronary risk factors, number of diseased vessels, or exercise tolerance at baseline were observed between the 2 groups. In addition, the length of hospital stay was not significantly different between the

5 Physical Activity and Coronary Plaque in ACS 5 Table 3. Comparison of IVUS Data Between the Intensive and Standard Groups Intensive CR group (n=18) Standard CR group (n=14) Before After P-value Before After P-value IVUS profile Length (mm) 12.1± ± ± ±5.9 Vessel volume (mm 3 ) 198.5± ±125.1 < ± ±99.8 <0.01 Lumen volume (mm 3 ) 111.3± ± ± ± PV (mm 3 ) 87.2± ±54.5 < ± ± Percent change of PV 8.9± ±5.5 IB-IVUS profile LV (mm 3 ) 27.4± ± ± ± FV (mm 3 ) 30.4± ± ± ± DFV (mm 3 ) 3.2± ± ± ± CV (mm 3 ) 0.58± ± ± ± Percent of LV (%) 38.4± ± ± ± Percent of FV (%) 54.2± ± ± ± Percent of DFV (%) 6.1± ± ± ± Percent of CV (%) 1.1± ± ± ± Percent change of LV 8.0± ±24.3 Data given as mean ± SD. CR, cardiac rehabilitation; CV, calcified volume; DFV, dense fibrous volume; FV, fibrous volume; IB-IVUS, integrated backscatter intravascular ultrasound; IVUS, intravascular ultrasound; LV, lipid volume; PV, plaque volume. Figure 2. Physical activity for each patient during late phase II cardiac rehabilitation. standard and intensive groups (12.2±3.4 vs. 11.7±4.3 days, P=0.76). The number of late phase II CR sessions was not significantly different between the 2 groups. Furthermore, there were no significant difference in clinical characteristics between the 2 groups, which was analyzed in all entry patients (data not shown). Serum Lipid Profiles and Glucose Parameters Serum lipid profiles and glucose parameters at baseline and after 8 months are listed in Table 2. At baseline, there were no significant differences between the 2 groups. At 8 months, low-density lipoprotein cholesterol (LDL-C) was significantly lower than at baseline in both groups (both P<0.01). In the standard group, serum fasting glucose significantly decreased after 8 months compared with baseline (from 132±50 to 101±16 mg/dl, P<0.05). After 8 months, hemo- globin A1c (HbA1c) was significantly lower in the intensive group than in the standard group (5.8%±0.4% vs. 6.2%± 0.7%, P<0.05). Anthropometry, Exercise Tolerance, and Daily PA Anthropometric parameters, exercise tolerance, and PA at baseline and after 8 months in each group are listed in Table 2. Anthropometry at baseline was not significantly different between the 2 groups. After 8 months, waist circumference (WC) was significantly lower than at baseline in both groups (both P<0.05). At baseline, peak V O2 was not different between the 2 groups. At 8-month follow-up, both groups showed significant improvements in exercise tolerance (both P<0.05). Participation in late phase II CR and PA did not differ significantly between the 2 groups.

6 6 NISHITANI-YOKOYAMA M et al. Table 4. Comparison of IVUS Data Between the Active and Inactive Groups Active group (n=12) Inactive group (n=20) Before After P-value Before After P-value IVUS profile Length (mm) 12.1± ± ± ±5.6 Vessel volume (mm 3 ) 183.0± ±100.2 < ± ±125.6 <0.01 Lumen volume (mm 3 ) 101.2± ± ± ± PV (mm 3 ) 81.8± ±39.9 < ± ± Percent change of PV 12.5±9.4* 3.6±11.3 IB-IVUS profile LV (mm 3 ) 21.4± ± ± ± FV (mm 3 ) 32.2± ± ± ± DFV (mm 3 ) 3.5± ± ± ± CV (mm 3 ) 0.5± ± ± ± Percent of LV (%) 35.4± ± ± ± Percent of FV (%) 52.7± ± ± ± Percent of DFV (%) 6.2± ± ± ± Percent of CV (%) 1.0± ± ± ± Percent change of LV 17.5±19.1** 7.7±25.6 Data given as mean ± SD. *P<0.05 vs. inactive group after intervention; **P<0.01 vs. inactive group after intervention. Abbreviations as in Tables 2,3. Figure 3. Percent change in (A,C) plaque volume (PV) and (B,D) lipid volume (LV) according to (A,B) level of daily physical activity and (C,D) steps/day in acute coronary syndrome patients undergoing cardiac rehabilitation. IVUS Parameter Volumetry Volumetric IVUS parameter analysis is given in Table 3. At baseline, there were no significant differences in vessel volume, lumen volume, or PV between the 2 groups. At 8-month follow-up, PV was reduced in both groups (both P<0.05). The percent change in PV, however, did not significantly differ between the intensive and standard groups ( 8.9±14.2% vs. 4.5±5.5%, P=0.28).

7 Physical Activity and Coronary Plaque in ACS 7 Table 5. Significant Indicators of Percent Change of PV and of LV Univariate analysis Multivariate analysis β P-value β P-value A. Percent change of PV Age Sex Classification of ACS Diabetes (absent-present) Ejection fraction Delta waist circumference Delta fasting glucose Physical activity <0.01 Delta peak V O <0.01 Delta LDL-C 0.56 < <0.01 Delta HDL-C Plaque volume at baseline Lipid volume at baseline B. Percent change of LV Age Sex Classification of ACS Diabetes (absent-present) Ejection fraction Delta waist circumference Delta fasting glucose Physical activity 0.45 < Delta peak V O Delta LDL-C Delta HDL-C PV at baseline LV at baseline β, standardized partial regression coefficient. Other abbreviations as in Tables 1 3. IB-IVUS Parameters At baseline, the volume of each component did not significantly differ between the 2 groups (Table 3). At follow-up, absolute LV and FV were significantly decreased in the intensive CR group (from 27.4±29.7 to 24.1±26.1 mm 3, P=0.01 and from 30.4±21.0 to 26.3±18.5 mm 3, P=0.03, respectively), whereas these did not differ significantly in the standard group. Percent change in LV was not significantly different between the intensive and standard groups ( 8.0%±24.9% vs. 6.4%±24.3%, P=0.12). Active vs. Inactive Groups Figure 2 shows PA for a period of 60 days after discharge for each patient. According to the PA records, 58% of patients did not achieve the target exercise level in the intensive CR group and 40% of patients exceeded the target exercise level in the standard CR group. Therefore, the subjects were classified into the following 2 groups according to median PA (i.e., 7,000 steps): active group (n=12), daily PA 7,000 steps; and inactive group (n=20), daily PA <7,000 steps. At baseline, there were no significant differences in clinical characteristics between the 2 groups, except ejection fraction (Table S1). At 8 months, LDL-C was significantly lower than at baseline in both groups (both P<0.01). In the active group, fasting glucose significantly decreased after 8 months compared with baseline (from 128±54 to 97±15 mg/dl, P<0.05). After 8 months, high-density lipoprotein cholesterol (HDL-C) was significantly higher in the active group than in the inactive group (45±10 vs. 38±8 mg/dl, P<0.05). At 8 months, WC was significantly lower than at baseline in both groups (both P<0.05). In the active group, hip circumference (from 96.0±7.1 to 92.0±6.0 cm, P<0.01) and fat weight (from 18.5±6.2 to 14.6±5.8 kg, P<0.01) were significantly decreased compared with baseline. At baseline, peak V O2 was not significantly different between the 2 groups. At 8-month follow-up, both groups had significant improvements in exercise tolerance. In the active group, exercise tolerance was significantly higher than in the inactive group (22.9±4.6 vs. 19.4±2.8 ml/kg/min, P=0.01; Table S2). Volumetric analysis of the IVUS parameters is given in Table 4. At baseline, there was no significant difference in vessel volume, lumen volume, or PV between the 2 groups. At 8-month follow-up, PV was reduced in both groups (both P<0.05). Percent change in PV was significantly different between the active and inactive groups ( 12.5%± 9.4% vs. 3.6%±11.3%, P=0.02; Figure 3A). At baseline, the volume of each component was not significantly different between the 2 groups (Table 4). The absolute change in LV was significantly decreased in the active group (21.4±17.8 to 17.5±14.2 mm 3, P=0.01), unlike in the inactive group (24.1±8.7 to 23.1±25.0 mm 3, P=0.39). Percent change in LV

8 8 NISHITANI-YOKOYAMA M et al. was also significantly different between the active and inactive groups ( 17.5%±19.1% vs. 7.7%±25.6%, P<0.01; Figure 3B). Plaque Change and PA Percent change in PV and in LV with regard to PA is shown in Figure 3C,D, respectively. Percent change in PV (r= 0.43, P=0.01) and in LV (r= 0.45, P<0.01) was significantly negatively correlated with PA. Exercise tolerance was highly and positively correlated with PA. Therefore, we performed multivariable linear regression analyses. On multivariate analysis including age, sex, classification of ACS, presence or absence of diabetes, ejection fraction, change in WC, change in fasting glucose, PA, change in LDL-C, change in HDL-C, PV at baseline and LV at baseline, PA (β= 0.41, P<0.01) and change in LDL-C (β=0.47, P<0.01) were significantly associated with the change in percent PV (Table 5). On multivariate analysis, including the same parameters, only PA was significantly associated with the change in percent LV (β= 0.42, P=0.01; Table 5). Discussion In the present study, there was no significant difference in the change of plaque regression or of components between the intensive and standard CR groups. HbA1c, however, was significantly lower in the intensive group than in the standard group at 8 months; absolute PV was significantly reduced in both groups, whereas absolute FV and LV were significantly reduced in the intensive group at 8 months; intensive PA significantly retarded coronary PV and ameliorated lipid component; and percent change in PV and in the lipid component was significantly and independently correlated with PA. This is the first study investigating the impact of PA on coronary PV and components using IB- IVUS in patients with ACS participating in late phase II CR. A possible explanation for the absence of significant difference in coronary PV and components between the intensive and standard groups may be the difference in training intensity during the study period. In the present study, 58% of patients assigned to the intensive CR group unexpectedly had lower PA intensity than prescribed, whereas 49% of those assigned to the standard CR group had higher PA intensity than prescribed. Achieving >9,000 steps may be difficult in an ordinary CR program. 14 In addition, participation in late phase II CR was not significantly different between the 2 groups. HbA1c and LV, however, were significantly reduced in the intensive group. Therefore, more aggressive participation in late phase II CR may affect PV and components. There are several mechanisms via which the percent change in PV and LV significantly decreased in the active group. Hambrecht et al reported that regression of coronary atherosclerotic lesions was observed in patients with CAD expending an average of 2,200kcal/week during regular physical exercise. 15 In this study, the calculated mean energy expenditure during PA in the active and inactive groups was 297±66 kcal/day (almost 2,000 kcal/week) and 146±45 kcal/day (almost 1,000 kcal/week), respectively. In the Nakanojo study, moderate intensity daily activity was associated with arteriosclerosis, osteoporosis, and sarcopenia. 16 We prescribed an intensity of exercise of approximately 3.5 metabolic equivalents measured using CPX at discharge. Thus, the present PA regimen may be sufficient to reduce PV and change plaque components. At 8-month follow-up, exercise tolerance significantly increased in the active group compared with the inactive group. Yoshikawa et al reported that high exercise tolerance is an independent predictor of coronary plaque composition and fibrous cap thickness in non-culprit lesions in patients with angina pectoris assessed on IB-IVUS and optical coherence tomography. 17 LDL-C, LDL-C/HDL-C ratio, and exercise tolerance at 8 months significantly improved in both groups. In patients with ACS, we previously reported using IVUS that early aggressive lipid-lowering therapy using atorvastatin for 6 months significantly reduced PV. 9 Therefore, changes in these lipid profiles and coronary plaque may be partly induced by statins. At 8 months, HDL-C was significantly higher in the active group than in the inactive group in the present study. Regular exercise increases HDL-C, which is associated with reverse cholesterol transport, LDL antioxidation, endothelial protection, antiplatelet activity, and anticoagulation. 18 Moreover, increased cytokines, such as interleukin (IL)-6 and monocyte chemoattractant protein-1, have been reported in patients with ACS. 19 Walther et al reported that regular physical exercise is associated with a reduction of inflammatory markers and ischemic events in patients with CAD. 20,21 We reported that 6-month CR ameliorated metabolic parameters, exercise capacity, muscle strength, and the inflammatory state in patients with metabolic syndrome following CABG. 13 Furthermore, animal studies reported that exercise improves endothelial dysfunction and the formation of atherosclerotic lesions through anti-inflammatory effects. 22 At 8-month follow-up, IL-6 was low in the active group compared with the inactive group and was significantly and inversely correlated with exercise tolerance and PA (data not shown). This suggests that improvement in lipid profile and reduction of pro-inflammatory cytokines ameliorate plaque progression and plaque components. Step count was done using a pedometer. This device is easy to use and is, thus, appropriate for self-monitoring and quantifying PA. Furthermore, the pedometer step count reflects exercise tolerance, correlates with several vascular or metabolic markers, and enhances PA as a motivational tool. 23 Therefore, CR involving intensive PA monitoring using a pedometer may serve as an additional strategy for residual cardiovascular risk in patients with ACS. Study Limitations The present study is characterized by a number of limitations. First, this was a single-center study with a small sample size. To the best of our knowledge, this is the first study to investigate the effect of CR on coronary plaque regression and stabilization using IB-IVUS. Therefore, it is difficult to calculate the appropriate sample size for an exploratory study. We had previously demonstrated that coronary plaque changes were significantly and negatively correlated with PA using grayscale IVUS in 46 patients with ACS. 6 Therefore, we decided that the required sample size was >50 patients in this study. Studies with a larger sample size are warranted to confirm these findings. Second, a pedometer is unable to provide information regarding non-walking-related activities. Therefore, the evaluation of daily activity may have been underestimated. Third, we enrolled patients receiving CR following ACS. Therefore, the present results may not be representative of all patients with CAD.

9 Physical Activity and Coronary Plaque in ACS 9 Conclusions No significant difference was observed in PV or components between the intensive CR and the standard CR groups. Intensive PA, however, may retard coronary PV and ameliorate the lipid component in patients with ACS participating in late- phase II CR. Late phase II CR, including a program that encourages increased PA, may exert beneficial effects on both the regression and stabilization of coronary plaque in patients with ACS. Acknowledgments This work was supported by JSPS KAKENHI Grant Number JP15K The authors thank Megumi Matsumoto and Yumi Nozawa for their assistance in this study. We greatly acknowledge the contributions made by Nao Naito to IVUS core laboratory management and IVUS planimetry. Disclosure The authors declare no conflicts of interest. References 1. O Connor GT, Buring JE, Yusuf S, Goldhaber SZ, Olmstead EM, Paffenbarger RS Jr, et al. An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation 1989; 80: Taylor RS, Brown A, Ebrahim S, Jolliffe J, Noorani H, Rees K, et al. Exercise-based rehabilitation for patients with coronary heart disease: Systematic review and meta-analysis of randomized controlled trials. Am J Med 2004; 116: The Japanese Circulation Society. Guidelines for rehabilitation in patients with cardiovascular disease (JCS 2012). (accessed May 31, 2018) (in Japanese). 4. Tani S, Nagao K, Anazawa T, Kawamata H, Furuya S, Takahashi H, et al. Coronary plaque regression and lifestyle modification in patients treated with pravastatin: Assessment mainly by daily aerobic exercise and an increase in the serum level of high-density lipoprotein cholesterol. Circ J 2010; 74: Kurose S, Iwasaka J, Tsutsumi H, Yamanaka Y, Shinno H, Fukushima Y, et al. Effect of exercise-based cardiac rehabilitation on non-culprit mild coronary plaques in the culprit coronary artery of patients with acute coronary syndrome. Heart Vessels 2016; 31: Nishitani-Yokoyama M, Miyauchi K, Shimada K, Miyazaki T, Ogita M, Okazaki S, et al. Effects of phase ii comprehensive cardiac rehabilitation on coronary plaque volume after acute coronary syndrome. Int Heart J 2015; 56: Kawasaki M, Sano K, Okubo M, Yokoyama H, Ito Y, Murata I, et al. Volumetric quantitative analysis of tissue characteristics of coronary plaques after statin therapy using three-dimensional integrated backscatter intravascular ultrasound. J Am Coll Cardiol 2005; 45: Kawasaki M, Takatsu H, Noda T, Sano K, Ito Y, Hayakawa K, et al. In vivo quantitative tissue characterization of human coronary arterial plaques by use of integrated backscatter intravascular ultrasound and comparison with angioscopic findings. Circulation 2002; 105: Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, et al. Early statin treatment in patients with acute coronary syndrome: Demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: The ESTABLISH Study. Circulation 2004; 110: Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: A multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin. J Am Coll Cardiol 2009; 54: Kojima T, Miyauchi K, Yokoyama T, Yokoyama K, Kurata T, Suwa S, et al. Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo University. Circ J 2011; 75: Seki E, Watanabe Y, Shimada K, Sunayama S, Onishi T, Kawakami K, et al. Effects of a phase III cardiac rehabilitation program on physical status and lipid profiles in elderly patients with coronary artery disease: Juntendo Cardiac Rehabilitation Program (J-CARP). Circ J 2008; 72: Onishi T, Shimada K, Sunayama S, Ohmura H, Sumide T, Masaki Y, et al. Effects of cardiac rehabilitation in patients with metabolic syndrome after coronary artery bypass grafting. J Cardiol 2009; 53: Ellingsen Ø, Halle M, Conraads V, Støylen A, Dalen H, Delagardelle C, et al. High-intensity interval training in patients with heart failure with reduced ejection fraction. Circulation 2017; 135: Hambrecht R, Niebauer J, Marburger C, Grunze M, Kälberer B, Hauer K, et al. Various intensities of leisure time physical activity in patients with coronary artery disease: Effects on cardiorespiratory fitness and progression of coronary atherosclerotic lesions. J Am Coll Cardiol 1993; 22: Aoyagi Y, Shephard RJ. Habitual physical activity and health in the elderly: The Nakanojo Study. Geriatr Gerontol Int 2010; 10: S236 S Yoshikawa D, Ishii H, Kurebayashi N, Sato B, Hayakawa S, Ando H, et al. Association of cardiorespiratory fitness with characteristics of coronary plaque: Assessment using integrated backscatter intravascular ultrasound and optical coherence tomography. Int J Cardiol 2013; 162: Koba S, Tanaka H, Maruyama C, Tada N, Birou S, Teramoto T, et al. Physical activity in the Japan population: Association with blood lipid levels and effects in reducing cardiovascular and all-cause mortality. J Atheroscler Thromb 2011; 18: Hojo Y, Ikeda U, Takahashi M, Shimada K. Increased levels of monocyte-related cytokines in patients with unstable angina. Atherosclerosis 2002; 161: Walther C, Möbius-Winkler S, Linke A, Bruegel M, Thiery J, Schuler G, et al. Regular exercise training compared with percutaneous intervention leads to a reduction of inflammatory markers and cardiovascular events in patients with coronary artery disease. Eur J Cardiovasc Prev Rehabil 2008; 15: Schumacher A, Peersen K, Sommervoll L, Seljeflot I, Arnesen H, Otterstad JE. Physical performance is associated with markers of vascular inflammation in patients with coronary heart disease. Eur J Cardiovasc Prev Rehabil 2006; 13: Fukao K, Shimada K, Naito H, Sumiyoshi K, Inoue N, Iesaki T, et al. Voluntary exercise ameliorates the progression of atherosclerotic lesion formation via anti-inflammatory effects in apolipoprotein E-deficient mice. J Atheroscler Thromb 2010; 17: Cao ZB, Miyatake N, Higuchi M, Ishikawa-Takata K, Miyachi M, Tabata I. Prediction of VO2 max with daily step counts for Japanese adult women. Eur J Appl Physiol 2009; 105: Supplementary Files Supplementary File 1 Table S1. Baseline patient characteristics Table S2. Comparison of anthropometric parameters, exercise tolerance, physical activity and lipid profiles between the active and inactive groups Please find supplementary file(s);

ZEUS Trial ezetimibe Ultrasound Study

ZEUS Trial ezetimibe Ultrasound Study Trial The lower, The better Is it True for Plaque Regression? Statin alone versus Combination of Ezetimibe and Statin Juntendo University, Department of Cardiology, Tokyo, Japan Katsumi Miyauchi, Naohisa

More information

Effects of a Phase III Cardiac Rehabilitation Program on Physical Status and Lipid Profiles in Elderly Patients With Coronary Artery Disease

Effects of a Phase III Cardiac Rehabilitation Program on Physical Status and Lipid Profiles in Elderly Patients With Coronary Artery Disease Circ J 2008; 72: 1230 1234 Effects of a Phase III Cardiac Rehabilitation Program on Physical Status and Lipid Profiles in Elderly Patients With Coronary Artery Disease Juntendo Cardiac Rehabilitation Program

More information

Culprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome

Culprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome Culprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome Hiroyuki Okura*, MD; Nobuya Matsushita**,MD Kenji Shimeno**, MD; Hiroyuki Yamaghishi**, MD Iku Toda**,

More information

Cardiovascular Research Foundation and Columbia University Medical Center, New York.

Cardiovascular Research Foundation and Columbia University Medical Center, New York. Virtual Histology Intravascular Ultrasound Analysis of Non-culprit Attenuated Plaques Detected by Grayscale Intravascular Ultrasound in Patients with Acute Coronary Syndromes Xiaofan Wu, Akiko Maehara,

More information

Division of Cardiovascular Medicine, Jichi Medical University Saitama Medical Center, Japan

Division of Cardiovascular Medicine, Jichi Medical University Saitama Medical Center, Japan Association between continuously elevated C-reactive protein and restenosis after percutaneous coronary intervention using drug-eluting stent in angina patients Division of Cardiovascular Medicine, Jichi

More information

APPENDIX F: CASE REPORT FORM

APPENDIX F: CASE REPORT FORM APPENDIX F: CASE REPORT FORM Instruction: Complete this form to notify all ACS admissions at your centre to National Cardiovascular Disease Registry. Where check boxes are provided, check ( ) one or more

More information

Assessment of plaque morphology by OCT in patients with ACS

Assessment of plaque morphology by OCT in patients with ACS Assessment of plaque morphology by OCT in patients with ACS Takashi Akasaka, M.D. Department of Cardiovascular Medicine Wakayama, Japan Unstable plaque Intima Lipid core Plaque rupture and coronary events

More information

COURAGE to Leave Diseased Arteries Alone

COURAGE to Leave Diseased Arteries Alone COURAGE to Leave Diseased Arteries Alone Spencer King MD MACC, FSCAI St. Joseph s s Heart and Vascular Institute Professor of Medicine Emeritus Emory Univ. Atlanta, USA Conflict: I am an Interventionalist

More information

Comparison of the low-density lipoprotein cholesterol target value and the preventive effect of statins in elderly patients and younger patients

Comparison of the low-density lipoprotein cholesterol target value and the preventive effect of statins in elderly patients and younger patients Journal of Geriatric Cardiology (2017) 14: 383 391 2017 JGC All rights reserved; www.jgc301.com Research Article Open Access Comparison of the low-density lipoprotein cholesterol target value and the preventive

More information

DECLARATION OF CONFLICT OF INTEREST. Nothing to disclose

DECLARATION OF CONFLICT OF INTEREST. Nothing to disclose DECLARATION OF CONFLICT OF INTEREST Nothing to disclose Four-Year Clinical Outcomes of the OLIVUS (Impact of OLmesartan on progression of coronary atherosclerosis; evaluation by IntraVascular UltraSound

More information

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor 76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class

More information

Clinical Considerations of High Intensity Interval Training (HIIT)

Clinical Considerations of High Intensity Interval Training (HIIT) Clinical Considerations of High Intensity Interval Training (HIIT) Jenna Taylor Exercise Physiologist & Dietitian The Wesley Hospital PhD Candidate The University of Queensland What is High Intensity Interval

More information

Intravascular Ultrasound

Intravascular Ultrasound May 2008 Beth Israel Deaconess Medical Center Harvard Medical School Intravascular Ultrasound Matthew Altman, HMS III Gillian Lieberman, MD BIDMC Department of Radiology Presentation Overview 1. Patient

More information

Acute Myocardial Infarction. Willis E. Godin D.O., FACC

Acute Myocardial Infarction. Willis E. Godin D.O., FACC Acute Myocardial Infarction Willis E. Godin D.O., FACC Acute Myocardial Infarction Definition: Decreased delivery of oxygen and nutrients to the myocardium Myocardial tissue necrosis causing irreparable

More information

Epicardial fat volume as a predictor of coronary vulnerable plaques using cardiac computed tomography in the patients with zero calcium score

Epicardial fat volume as a predictor of coronary vulnerable plaques using cardiac computed tomography in the patients with zero calcium score ESC Congress 2011 Epicardial fat volume as a predictor of coronary vulnerable plaques using cardiac computed tomography in the patients with zero calcium score K. Harada, N. Terada, A. Okada, M. Shigekiyo,

More information

4. Which survey program does your facility use to get your program designated by the state?

4. Which survey program does your facility use to get your program designated by the state? STEMI SURVEY Please complete one survey for each TCD designation you have in your facility. There would be a maximum of three surveys completed if your facility was designated as a trauma, stroke and STEMI

More information

Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes?

Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes? Late Breaking Clinical Trial Session at AHA 2017 Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes? The REAL-CAD Study in 13,054 Patients With Stable Coronary Artery Disease Takeshi

More information

Ichiro Matsumoto, MD; Yuichi Miyake, MD; Mizuki Mizukawa, MD; Yuichiro Takagi, MD

Ichiro Matsumoto, MD; Yuichi Miyake, MD; Mizuki Mizukawa, MD; Yuichiro Takagi, MD Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp ORIGINAL ARTICLE Ischemic Heart Disease Impact of Low-Density Lipoprotein Cholesterol/ High-Density Lipoprotein

More information

Qui dois-je adresser en réadaptation cardiaque? Who must I refer in cardiac rehabilitation?

Qui dois-je adresser en réadaptation cardiaque? Who must I refer in cardiac rehabilitation? Atelier pratique How to session Qui dois-je adresser en réadaptation cardiaque? Who must I refer in cardiac rehabilitation? Un patient coronarien A patient with coronary artery disease Jeudi 14 janvier

More information

Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial

Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators

More information

Impact of Metabolic Syndrome on Tissue Characteristics of Angiographically Mild to Moderate Coronary Lesions

Impact of Metabolic Syndrome on Tissue Characteristics of Angiographically Mild to Moderate Coronary Lesions Journal of the American College of Cardiology Vol. 49, No. 11, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.12.028

More information

Acute Myocardial Infarction

Acute Myocardial Infarction Acute Myocardial Infarction Hafeza Shaikh, DO, FACC, RPVI Lourdes Cardiology Services Asst.Program Director, Cardiology Fellowship Associate Professor, ROWAN-SOM Acute Myocardial Infarction Definition:

More information

PCSK9 Inhibitors and Modulators

PCSK9 Inhibitors and Modulators PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s

More information

Coronary Artery Disease: Revascularization (Teacher s Guide)

Coronary Artery Disease: Revascularization (Teacher s Guide) Stephanie Chan, M.D. Updated 3/15/13 2008-2013, SCVMC (40 minutes) I. Objectives Coronary Artery Disease: Revascularization (Teacher s Guide) To review the evidence on whether percutaneous coronary intervention

More information

Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome

Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome Helder Dores, Luís Bronze Carvalho, Ingrid Rosário, Sílvio Leal, Maria João

More information

Coronary Artery Disease Clinical Practice Guidelines

Coronary Artery Disease Clinical Practice Guidelines Coronary Artery Disease Clinical Practice Guidelines Guidelines are systematically developed statements to assist patients and providers in choosing appropriate healthcare for specific clinical conditions.

More information

In-Ho Chae. Seoul National University College of Medicine

In-Ho Chae. Seoul National University College of Medicine The Earlier, The Better: Quantum Progress in ACS In-Ho Chae Seoul National University College of Medicine Quantum Leap in Statin Landmark Trials in ACS patients Randomized Controlled Studies of Lipid-Lowering

More information

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003 Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,

More information

Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion

Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion Hyeon-Cheol Gwon Cardiac and Vascular Center Samsung Medical Center Sungkyunkwan University School of Medicine Dr. Hyeon-Cheol

More information

Declaration of conflict of interest. Nothing to disclose

Declaration of conflict of interest. Nothing to disclose Declaration of conflict of interest Nothing to disclose Hong-Seok Lim, Seung-Jea Tahk, Hyoung-Mo Yang, Jin-Woo Kim, Kyoung- Woo Seo, Byoung-Joo Choi, So-Yeon Choi, Myeong-Ho Yoon, Gyo-Seung Hwang, Joon-Han

More information

대한심장학회춘계학술대회 Satellite Symposium

대한심장학회춘계학술대회 Satellite Symposium 대한심장학회춘계학술대회 Satellite Symposium Coronary Plaque Regression and Compositional Changes by Lipid-Lowering Therapy: IVUS Substudy in Livalo (Pitavastatin) in Acute Myocardial Infarction Study (LAMIS) Livalo

More information

TCTAP Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI

TCTAP Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI Indian TUXEDO Trial In Medically Treated Diabetics Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI Executive Director and Dean Escorts Heart Institute & Medical Research Center and Fortis Hospitals, New Delhi

More information

Intervention: How and to which extent is technology helping us?

Intervention: How and to which extent is technology helping us? Cardiological Society of India Congress 12th February 2016 Chennai, India Intervention: How and to which extent is technology helping us? SIMONE BISCAGLIA MD CARDIOVASCULAR INSTITUTE, FERRARA, ITALY Introduction

More information

Unprotected LM intervention

Unprotected LM intervention Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline

More information

Cardiovascular Disorders Lecture 3 Coronar Artery Diseases

Cardiovascular Disorders Lecture 3 Coronar Artery Diseases Cardiovascular Disorders Lecture 3 Coronar Artery Diseases By Prof. El Sayed Abdel Fattah Eid Lecturer of Internal Medicine Delta University Coronary Heart Diseases It is the leading cause of death in

More information

Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD

Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Mun K. Hong, MD Associate Professor of Medicine Director, Cardiovascular Intervention and Research Weill Cornell

More information

Case Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA

Case Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA Case Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA Case History A 50-year-old man with type 1 diabetes mellitus and hypertension presents after experiencing 1 hour of midsternal chest pain that began after

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response

More information

Value of cardiac rehabilitation Prof. Dr. L Vanhees

Value of cardiac rehabilitation Prof. Dr. L Vanhees Session: At the interface of hypertension and coronary heart disease haemodynamics, heart and hypertension Value of cardiac rehabilitation Prof. Dr. L Vanhees ESC Stockholm August 2010 Introduction There

More information

LM stenting - Cypher

LM stenting - Cypher LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with

More information

CLINICAL APPLICATIONS OF OPTICAL COHERENCE TOMOGRAPHY. Konstantina P. Bouki, FESC 2 nd Department of Cardiology General Hospital Of Nikea, Pireaus

CLINICAL APPLICATIONS OF OPTICAL COHERENCE TOMOGRAPHY. Konstantina P. Bouki, FESC 2 nd Department of Cardiology General Hospital Of Nikea, Pireaus CLINICAL APPLICATIONS OF OPTICAL COHERENCE TOMOGRAPHY Konstantina P. Bouki, FESC 2 nd Department of Cardiology General Hospital Of Nikea, Pireaus OPTICAL COHERENCE TOMOGRAPHY (OCT) IVUS and OCT IVUS OCT

More information

Invasive Coronary Imaging Modalities for Vulnerable Plaque Detection

Invasive Coronary Imaging Modalities for Vulnerable Plaque Detection Invasive Coronary Imaging Modalities for Vulnerable Plaque Detection Gary S. Mintz, MD Cardiovascular Research Foundation New York, NY Greyscale IVUS studies have shown Plaque ruptures do not occur randomly

More information

Quinn Capers, IV, MD

Quinn Capers, IV, MD Heart Attacks Mended Hearts Presentation, January, 2017 Quinn Capers, IV, MD Associate Professor of Medicine (Cardiovascular Medicine) Director, Transradial Coronary Interventions Division of Cardiovascular

More information

ARMYDA-RECAPTURE (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) trial

ARMYDA-RECAPTURE (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) trial ARMYDA-RECAPTURE ( for Reduction of MYocardial Damage during Angioplasty) trial Prospective, multicenter, randomized, double blind trial investigating efficacy of atorvastatin reload in patients on chronic

More information

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,

More information

Clinical Trial Synopsis TL-OPI-518, NCT#

Clinical Trial Synopsis TL-OPI-518, NCT# Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride

More information

Importance of the third arterial graft in multiple arterial grafting strategies

Importance of the third arterial graft in multiple arterial grafting strategies Research Highlight Importance of the third arterial graft in multiple arterial grafting strategies David Glineur Department of Cardiovascular Surgery, Cliniques St Luc, Bouge and the Department of Cardiovascular

More information

Best Lipid Treatments

Best Lipid Treatments Best Lipid Treatments Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Overview of Talk Review of pathogenesis

More information

Intravascular ultrasound-based analysis of factors affecting minimum lumen area in coronary artery intermediate lesions

Intravascular ultrasound-based analysis of factors affecting minimum lumen area in coronary artery intermediate lesions Journal of Geriatric Cardiology (2016) 13: 169 174 2016 JGC All rights reserved; www.jgc301.com Research Article Open Access Intravascular ultrasound-based analysis of factors affecting minimum lumen area

More information

Management of Stable Ischemic Heart Disease. Vinay Madan MD February 10, 2018

Management of Stable Ischemic Heart Disease. Vinay Madan MD February 10, 2018 Management of Stable Ischemic Heart Disease Vinay Madan MD February 10, 2018 1 Disclosure No financial disclosure. 2 Overview of SIHD Diagnosis Outline of talk Functional vs. Anatomic assessment Management

More information

Spotty Calcification as a Marker of Accelerated Progression of Coronary Atherosclerosis : Insights from Serial Intravascular Ultrasound

Spotty Calcification as a Marker of Accelerated Progression of Coronary Atherosclerosis : Insights from Serial Intravascular Ultrasound Spotty Calcification as a Marker of Accelerated Progression of Coronary Atherosclerosis : Insights from Serial Intravascular Ultrasound Department of Cardiovascular Medicine Heart and Vascular Institute

More information

Cardiovascular Complications of Diabetes

Cardiovascular Complications of Diabetes VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary

More information

Impact of Body Mass Index and Metabolic Syndrome on the Characteristics of Coronary Plaques Using Computed Tomography Angiography

Impact of Body Mass Index and Metabolic Syndrome on the Characteristics of Coronary Plaques Using Computed Tomography Angiography Impact of Body Mass Index and Metabolic Syndrome on the Characteristics of Coronary Plaques Using Computed Tomography Angiography Cardiovascular Division, Faculty of Medicine, University of Tsukuba Akira

More information

Stabilization and Regression of Coronary Plaques Treated With Pitavastatin Proven by Angioscopy and Intravascular Ultrasound

Stabilization and Regression of Coronary Plaques Treated With Pitavastatin Proven by Angioscopy and Intravascular Ultrasound Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp ORIGINAL ARTICLE Ischemic Heart Disease Stabilization and Regression of Coronary Plaques Treated With Pitavastatin

More information

STENTYS for Le, Main Sten2ng. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy

STENTYS for Le, Main Sten2ng. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy STENTYS for Le, Main Sten2ng Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy Disclosure Statement of Financial Interest I, Carlo Briguori DO NOT have a financial interest/ arrangement or affilia2on

More information

Title for Paragraph Format Slide

Title for Paragraph Format Slide Title for Paragraph Format Slide Presentation Title: Month Date, Year Atherosclerosis A Spectrum of Disease: February 12, 2015 Richard Cameron Padgett, MD Executive Medical Director, OHVI Pt RB Age 38

More information

HDL-C. J Jpn Coll Angiol, 2008, 48: NIPPON DATA80, MEGA study, JELIS, dyslipidemia, risk assessment chart

HDL-C. J Jpn Coll Angiol, 2008, 48: NIPPON DATA80, MEGA study, JELIS, dyslipidemia, risk assessment chart Online publication March 25, 2009 48 6 2007 2007 HDL-C LDL-C HDL-C J Jpn Coll Angiol, 2008, 48: 463 470 NIPPON DATA80, MEGA study, JELIS, dyslipidemia, risk assessment chart 1987 NIPPON DATA80 Iso 10 MRFIT

More information

Acute Coronary Syndrome. Sonny Achtchi, DO

Acute Coronary Syndrome. Sonny Achtchi, DO Acute Coronary Syndrome Sonny Achtchi, DO Objectives Understand evidence based and practice based treatments for stabilization and initial management of ACS Become familiar with ACS risk stratification

More information

Clinical Trial Synopsis TL-OPI-516, NCT#

Clinical Trial Synopsis TL-OPI-516, NCT# Clinical Trial Synopsis, NCT#00225277 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl Versus

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Leibowitz M, Karpati T, Cohen-Stavi CJ, et al. Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic

More information

Evidence-Based Management of CAD: Last Decade Trials and Updated Guidelines

Evidence-Based Management of CAD: Last Decade Trials and Updated Guidelines Evidence-Based Management of CAD: Last Decade Trials and Updated Guidelines Enrico Ferrari, MD Cardiac Surgery Unit Cardiocentro Ticino Foundation Lugano, Switzerland Conflict of Interests No conflict

More information

Perioperative Management After Coronary Stenting: Risk Assessment Before Surgery. Christian Seiler No conflict of interest to declare.

Perioperative Management After Coronary Stenting: Risk Assessment Before Surgery. Christian Seiler No conflict of interest to declare. Perioperative Management After Coronary Stenting: Risk Assessment Before Surgery Christian Seiler No conflict of interest to declare PCI Long-Term Outcome Perioperative Management After Coronary Stenting:

More information

Imaging Atheroma The quest for the Vulnerable Plaque

Imaging Atheroma The quest for the Vulnerable Plaque Imaging Atheroma The quest for the Vulnerable Plaque P.J. de Feijter 1. Department of Cardiology 2. Department of Radiology Coronary Heart Disease Remains the Leading Cause of Death in the U.S, Causing

More information

Clopidogrel Date: 15 July 2008

Clopidogrel Date: 15 July 2008 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov

More information

Cardiac Rehabilitation for Heart Failure Patients. Jia Shen MD, MPH Assistant Professor of Medicine UC San Diego Health System

Cardiac Rehabilitation for Heart Failure Patients. Jia Shen MD, MPH Assistant Professor of Medicine UC San Diego Health System Cardiac Rehabilitation for Heart Failure Patients Jia Shen MD, MPH Assistant Professor of Medicine UC San Diego Health System Disclosures There are no conflict of interests related to this presentation.

More information

Belinda Green, Cardiologist, SDHB, 2016

Belinda Green, Cardiologist, SDHB, 2016 Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens

More information

Clinical Practice Guideline

Clinical Practice Guideline Clinical Practice Guideline Secondary Prevention for Patients with Coronary and Other Vascular Disease Since the 2001 update of the American Heart Association (AHA)/American College of Cardiology (ACC)

More information

significantly associated in patients without a smoking history; however, no such association existed in patients with a smoking history.

significantly associated in patients without a smoking history; however, no such association existed in patients with a smoking history. Impact of smoking history on the association between Eicosapentaenoic acid to arachidonic acid ratio and acute coronary syndrome: A multicenter cross-sectional study Yuji Nishizaki 1, Kazunori Shimada

More information

PCI for Left Anterior Descending Artery Ostial Stenosis

PCI for Left Anterior Descending Artery Ostial Stenosis PCI for Left Anterior Descending Artery Ostial Stenosis Why do you hesitate PCI for LAD ostial stenosis? LAD Ostial Lesion Limitations of PCI High elastic recoil Involvement of the distal left main coronary

More information

Value of Cardiac Rehabilitation for Improving Patient Outcomes

Value of Cardiac Rehabilitation for Improving Patient Outcomes Value of Cardiac Rehabilitation for Improving Patient Outcomes Pam R. Taub MD, FACC Director of Step Family Cardiac Wellness and Rehabilitation Center Associate Professor of Medicine UC San Diego Health

More information

Low fractional diastolic pressure in the ascending aorta increased the risk of coronary heart disease

Low fractional diastolic pressure in the ascending aorta increased the risk of coronary heart disease (2002) 16, 837 841 & 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh ORIGINAL ARTICLE Low fractional diastolic pressure in the ascending aorta increased the risk

More information

Lessons learned From The National PCI Registry

Lessons learned From The National PCI Registry Lessons learned From The National PCI Registry w a v e On Behalf of The Publication Committee of the National PCI Registry Objectives & Anticipated Achievements To determine the epidemiology of patients

More information

Le# main treatment with Stentys stent. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy

Le# main treatment with Stentys stent. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy Le# main treatment with Stentys stent Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy Disclosure Statement of Financial Interest I, Carlo Briguori DO NOT have a financial interest/ arrangement

More information

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures

More information

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main

More information

Abstract Background: Methods: Results: Conclusions:

Abstract Background: Methods: Results: Conclusions: Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li

More information

Coronary Artery Bypass Grafting Versus Coronary Implantation of Sirolimus-Eluting Stents in Patients with Diabetic Retinopathy

Coronary Artery Bypass Grafting Versus Coronary Implantation of Sirolimus-Eluting Stents in Patients with Diabetic Retinopathy Coronary Artery Bypass Grafting Versus Coronary Implantation of Sirolimus-Eluting Stents in Patients with Diabetic Retinopathy Takayuki Ohno, MD, Shinichi Takamoto, MD, Noboru Motomura, MD, Minoru Ono,

More information

Supplementary Material to Mayer et al. A comparative cohort study on personalised

Supplementary Material to Mayer et al. A comparative cohort study on personalised Suppl. Table : Baseline characteristics of the patients. Characteristic Modified cohort Non-modified cohort P value (n=00) Age years 68. ±. 69.5 ±. 0. Female sex no. (%) 60 (0.0) 88 (.7) 0.0 Body Mass

More information

Assessing Cardiac Risk in Noncardiac Surgery. Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington

Assessing Cardiac Risk in Noncardiac Surgery. Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington Assessing Cardiac Risk in Noncardiac Surgery Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington Disclosure None. I have no conflicts of interest, financial or otherwise. CME

More information

DYSLIPIDEMIA RECOMMENDATIONS

DYSLIPIDEMIA RECOMMENDATIONS DYSLIPIDEMIA RECOMMENDATIONS Α. DIAGNOSIS Recommendation 1 INITIAL LIPID PROFILING (Level of evidence II) It is recommended to GPs and other PHC Physicians to assess the lipid profile {total cholesterol

More information

Usefulness of OCT during coronary intervention

Usefulness of OCT during coronary intervention Usefulness of OCT during coronary intervention Takashi Akasaka, M.D. Department of Cardiovascular Medicine Wakayama, Japan Predictors at 12 Months of Stent Thrombosis and Target Lesion Revascularization

More information

Changes in Coronary Plaque Color and Morphology by Lipid-Lowering Therapy With Atorvastatin: Serial Evaluation by Coronary Angioscopy

Changes in Coronary Plaque Color and Morphology by Lipid-Lowering Therapy With Atorvastatin: Serial Evaluation by Coronary Angioscopy Journal of the American College of Cardiology Vol. 42, No. 4, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)00770-8

More information

Lack of Effect of Beta-blocker Therapy in Patients with ST-elevation Acute Myocardial Infarction in PCI Era

Lack of Effect of Beta-blocker Therapy in Patients with ST-elevation Acute Myocardial Infarction in PCI Era Lack of Effect of Beta-blocker Therapy in Patients with ST-elevation Acute Myocardial Infarction in PCI Era B. Bao 1, N. Ozasa 1, T. Morimoto 2, Y. Furukawa 3, M. Shirotani 4, H. Ogawa 5, C. Tei 6, H.

More information

Exercise Studies Where Walking is Better than Running: Does Intensity Matter?

Exercise Studies Where Walking is Better than Running: Does Intensity Matter? Exercise Studies Where Walking is Better than Running: Does Intensity Matter? Frontiers in Medicine The Forest 24 September 2018 William E. Kraus, M.D. Exercise Intensity and Volume Effects: Confounded?

More information

Landmesser U et al. Eur Heart J 2017; https://doi.org/ /eurheartj/ehx549

Landmesser U et al. Eur Heart J 2017; https://doi.org/ /eurheartj/ehx549 2017 Update of ESC/EAS Task Force on Practical Clinical Guidance for PCSK9 inhibition in Patients with Atherosclerotic Cardiovascular Disease or in Familial Hypercholesterolaemia Cardiovascular Outcomes

More information

The PROSPECT Trial. A Natural History Study of Atherosclerosis Using Multimodality Intracoronary Imaging to Prospectively Identify Vulnerable Plaque

The PROSPECT Trial. A Natural History Study of Atherosclerosis Using Multimodality Intracoronary Imaging to Prospectively Identify Vulnerable Plaque The PROSPECT Trial Providing Regional Observations to Study Predictors of Events in the Coronary Tree A Natural History Study of Atherosclerosis Using Multimodality Intracoronary Imaging to Prospectively

More information

Serum Creatinine and Blood Urea Nitrogen Levels in Patients with Coronary Artery Disease

Serum Creatinine and Blood Urea Nitrogen Levels in Patients with Coronary Artery Disease Serum Creatinine and Blood Urea Nitrogen Levels in Patients with Coronary Artery Disease MAK Akanda 1, KN Choudhury 2, MZ Ali 1, MK Kabir 3, LN Begum 4, LA Sayami 1 1 National Institute of Cardiovascular

More information

Metabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology

Metabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology Metabolic Syndrome Shon Meek MD, PhD Mayo Clinic Florida Endocrinology Disclosure No conflict of interest No financial disclosure Does This Patient Have Metabolic Syndrome? 1. Yes 2. No Does This Patient

More information

Clinical Investigations

Clinical Investigations Clinical Investigations Risk Factors of Cardiac Troponin T Elevation in Patients with Stable Coronary Artery Disease After Elective Coronary Drug-Eluting Stent Implantation Zhang-Wei Chen, MD; Ju-Ying

More information

Impact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease

Impact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease Impact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease Gjin Ndrepepa, Tomohisa Tada, Massimiliano Fusaro, Lamin King, Martin Hadamitzky,

More information

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National

More information

CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand

CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand ENHANCED EXTERNAL COUNTER PULSATION Piyanuj Ruckpanich, MD. Cardiac Rehabilitation Center Perfect

More information

2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center

2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center 2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium Does Lt Late Cth Catch up Exist Eiti in DES? : Quantitative Coronary Angiography Analysis Kyung Woo Park, MD Cardiovascular

More information

The role of physical activity in the prevention and management of hypertension and obesity

The role of physical activity in the prevention and management of hypertension and obesity The 1 st World Congress on Controversies in Obesity, Diabetes and Hypertension (CODHy) Berlin, October 26-29 2005 The role of physical activity in the prevention and management of hypertension and obesity

More information

High Intensity Interval Exercise Training in Cardiac Rehabilitation

High Intensity Interval Exercise Training in Cardiac Rehabilitation High Intensity Interval Exercise Training in Cardiac Rehabilitation Prof. Leonard S.W. Li Hon. Clinical Professor, Department of Medicine, The University of Hong Kong Director, Rehabilitation Virtus Medical

More information

Coronary Artery Thermography

Coronary Artery Thermography Coronary Artery Thermography The 10th Anniversary, Interventional Vascular Therapeutics Angioplasty Summit 2005 TCT Asia Pacific Christodoulos Stefanadis Professor of Cardiology Athens Medical School In

More information

Methods Study population: From the Asan Medical Center (Seoul, Korea) clinical and IVUS core laboratory database,

Methods Study population: From the Asan Medical Center (Seoul, Korea) clinical and IVUS core laboratory database, Usefulness of Follow-Up Low-Density Lipoprotein Cholesterol Level as an Independent Predictor of Changes of Coronary Atherosclerotic Plaque Size as Determined by Intravascular Ultrasound Analysis After

More information

Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO!

Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO! Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO! Young-Hak Kim, MD, PhD Heart Institute, University of Ulsan College of Medicine Asan Medical Center,

More information

Rebuilding and Reinvigorating Cardiac Rehabilitation in 2018

Rebuilding and Reinvigorating Cardiac Rehabilitation in 2018 Rebuilding and Reinvigorating Cardiac Rehabilitation in 2018 Pam R. Taub MD, FACC Director of Step Family Cardiac Wellness and Rehabilitation Center Associate Professor of Medicine UC San Diego Health

More information